TB-500 vs Thymosin Beta-4: Sequence, Evidence, Identity
October 27, 2026 · STEPHAN ZOHAR
Thymosin beta-4 and TB-500 are different substances. Thymosin beta-4 (Tβ4, often written TB4) is a naturally occurring protein of about 43 amino acids. TB-500, in the way U.S. federal records and the analytical literature define it, is a short synthetic fragment of that protein: an N-acetylated seven-residue peptide, Ac-LKKTETQ. The two names are used interchangeably in marketing, but a laboratory that treats them as one material risks citing the wrong literature, ordering the wrong compound or misreading its own data.
This guide sets out what each name refers to, how the sequences relate, which findings belong to which molecule, what the FDA has said, and how a research lab can confirm what is actually in a vial. All peptides discussed are for laboratory research only and are not approved for human or veterinary use.
TL;DR
- Thymosin beta-4 is the full-length protein of roughly 43 residues. TB-500 is normally defined as its N-acetylated 17–23 fragment, Ac-LKKTETQ.
- “TB-4” normally means thymosin beta-4, not TB-500. Do not cite one molecule’s papers for the other without checking the sequence used.
- Most published biology concerns full-length thymosin beta-4. Direct TB-500 evidence is thin.
- Products labeled TB-500 have been found not to match their labels, so identity needs batch-matched HPLC, mass spectrometry and a Certificate of Analysis.
- In July 2026 the FDA proposed keeping TB-500 off the 503A bulk-drug list. That is not an approval of any kind.
Table of Contents
- The short answer: two names, two molecules
- What thymosin beta-4 is
- What TB-500 refers to
- Why “TB-4” causes confusion
- What the evidence covers
- Products labeled TB-500 do not always match the label
- How to verify a TB-500 or thymosin beta-4 sample
- Regulatory status in the United States
- Our perspective
- Sourcing TB-500 for laboratory work
- Related materials researchers confuse with TB-500
- FAQ
- Sources
The short answer: two names, two molecules
In scientifically precise usage, thymosin beta-4 and TB-500 are not synonyms. The FDA’s July 2026 briefing document on TB-500 treats TB-500 as a specific nominated substance, either free base or acetate, and separates that regulatory question from the identity of full-length thymosin beta-4. The NIH/FDA Global Substance Registration System (GSRS) agrees on the chemistry: its TB-500 record describes a seven-residue peptide, LKKTETQ, with N-terminal acetylation, and gives the common name “N-terminal acetylated 17–23 fragment of thymosin beta 4.”
The practical rule: unless a document expressly defines TB-500 as the full-length sequence, treat the two as different substances. That includes supplier pages, forum posts and papers.
| Feature | Thymosin beta-4 (Tβ4, TB4) | TB-500 |
|---|---|---|
| What it is | Naturally occurring protein | Synthetic peptide fragment |
| Length | About 43 residues | 7 residues |
| Sequence | Full-length beta-thymosin | Ac-LKKTETQ, residues 17–23 of Tβ4 |
| N-terminus | Acetylated native protein | N-terminal acetyl group on the fragment |
| Where most literature sits | Cell biology, wound healing, angiogenesis, reviews | A small number of analytical and preclinical studies |
| Typical shorthand | Tβ4, TB4, “TB-4” | TB-500, “thymosin beta-4 fragment” |
What thymosin beta-4 is
A 2021 review of secreted developmental peptides describes human thymosin beta-4 as a beta-thymosin, a family whose members have 43–44 amino-acid residues. Tβ4 is recognized in the literature as a multifunctional protein. A 2021 review of its function and applications links it to angiogenesis, cell migration and modulation of inflammation.
These properties belong to the full-length molecule or, in some studies, to its N- or C-terminal domains. That detail matters. A paper reporting a Tβ4 effect in a cell assay is not a paper about a seven-residue fragment, and the review literature is explicit about which domain was tested.
What TB-500 refers to
The name TB-500 entered circulation as a product label and was later characterized analytically. Esposito and colleagues’ 2012 study, Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4, identified Ac-LKKTETQ in a TB-500 formulation. The PubMed record for the same paper describes TB-500 as the material in which that heptapeptide was detected, not as full-length thymosin beta-4.
The Racing Medication and Testing Consortium’s TB-500 bulletin makes the same point from the testing side: thymosin beta-4 is the larger natural protein, while the product sold as TB-500 was marketed as an N-acetylated LKKTETQ peptide.
Sequence variants and fragments you will see
Readers who search for TB-500 sequence variants usually meet three situations:
- The canonical fragment. Ac-LKKTETQ, the 17–23 region, as recorded in GSRS.
- Metabolites of that fragment. In rats, TB-500 (Ac-LKKTETQ) was metabolized into Ac-LK and Ac-LKK, according to a 2024 quantification study. The same study suggests that wound-healing activities previously attributed to TB-500 may actually come from its metabolite Ac-LKKTE rather than the parent fragment.
- Loosely labeled products. Listings that say “TB-500” or “thymosin beta-4 fragment” without stating the sequence, terminal groups or salt form. Treat these as unspecified until a Certificate of Analysis says otherwise.
The second point has a consequence for design. If the active species is a downstream metabolite, an in vitro assay with the parent fragment and an in vivo experiment may not be measuring the same thing. Our own overview of how TB500 is described mechanistically covers what is and is not established.
Why “TB-4” causes confusion
People who type the shorthand TB-4 are almost always referring to thymosin beta-4. The FDA’s documentation supports this reading: TB-4 is shorthand for the full protein, not for TB-500. The confusion arises because vendors and forums use “TB-500 (thymosin beta-4)” as a single phrase, which collapses a 43-residue protein and a 7-residue fragment into one entry.
For a methods section or a purchase order, write the full identity. A line such as “Ac-LKKTETQ, N-terminal acetylated heptapeptide, acetate salt, lyophilized” leaves no ambiguity. A line reading “TB-500” does.
What the evidence covers
A 2026 review, Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, found that most included studies evaluated thymosin beta-4. Direct TB-500 evidence was limited to a single included study. This is the most important fact for anyone planning work around the fragment.
In practice, this means:
- Do not transfer Tβ4 results to TB-500. A finding on the full protein does not show that a seven-residue fragment reproduces it.
- Check the construct in every citation. Methods sections state whether full-length Tβ4, a domain or a fragment was used.
- Read pharmacokinetic claims carefully. Human studies have not measured the fragment, a gap we discuss in our note on TB500 half-life data.
- Keep preclinical and clinical language apart. Animal and cell data do not establish human outcomes.
The broader peptide field shows why this caution is warranted. Mendias and Awan (2026), in a review of approved and unapproved peptide therapies, note that unapproved peptides are marketed heavily for injury recovery while rigorous human safety data are scarce and the potential for serious harm is high, a risk made worse by placebo effects and social media influence.
Products labeled TB-500 do not always match the label
The RMTC bulletin reported that tested TB-500-labeled products were not consistently what their labels implied. It also noted that analyses at the Kenneth L. Maddy Laboratory at UC-Davis had found that many substances labeled TB-500 contained no thymosin beta-4 or associated peptides. That report is from 2016, but the lesson is current: a marketing name does not establish identity.
For a laboratory, this is a quality-control problem before it is a biology problem. If the vial does not contain Ac-LKKTETQ at the expected mass and purity, any downstream result is uninterpretable.
How to verify a TB-500 or thymosin beta-4 sample
Use this checklist on every incoming lot, regardless of supplier.
- Confirm the stated sequence and terminal groups. The label and Certificate of Analysis should give the full residue sequence, the N-terminal acetylation and the salt form. For TB-500, compare against the GSRS definition of Ac-LKKTETQ.
- Compare the expected mass with the mass spectrometry result. The observed mass should match the calculated mass of the stated sequence. A full-length protein and a heptapeptide differ by several thousand daltons, so this test separates them at once.
- Review the HPLC chromatogram. Look for a single dominant peak, the stated purity figure and any visible impurity shoulders. Our guide to HPLC versus mass spectrometry for peptide QC explains what each method can and cannot detect.
- Match the paperwork to the vial. The CoA, the vial label and the batch number must agree. A generic CoA that is not lot-specific is not evidence about your sample.
- Record storage conditions. Lyophilized peptides degrade when handled poorly. See our TB-500 storage guide for lab-grade handling.
If you are unsure how to interpret the numbers on a report, our walkthrough on reading a peptide Certificate of Analysis goes line by line.
Regulatory status in the United States
The FDA’s July 2026 review is the relevant regulatory source for U.S. readers. It proposed that neither TB-500 free base nor TB-500 acetate be included on the 503A bulk-drug list. A proposal not to list a substance for compounding is not an approval, and it is not a finding that the substance is safe or effective.
Two points follow for research use:
- Research-grade material is sold for laboratory work only. It is not a drug, a supplement or a product for human or veterinary use.
- Statuses change. Check the FDA’s current records and your institution’s compliance office before starting a protocol. Anti-doping bodies also list these substances, so anyone subject to athletic testing should consult the governing agency directly.
A registry entry for a Phase 1/2 study exists for a TB-500 (thymosin beta-4 17–23 fragment) program, but a registered trial is not a result. It tells you a question is being asked, not what the answer is.
Our perspective
We see the same problem in researcher inquiries again and again: a request for “TB-500” or “thymosin beta-4” with no sequence attached. The two names point to materials that differ in size, structure and literature, so we ask researchers to state which one they need before they order.
Our view is that identity documentation is the product. A research peptide is only as useful as the evidence that it is what the label says. That is why we publish third-party Certificates of Analysis per lot, with HPLC and mass spectrometry results, and why we sell to verified researchers only. We encourage every lab to repeat identity checks on receipt, ours included. Independent confirmation is how a result gets trusted.
We also think the field benefits from plain language. When a paper studies full-length Tβ4, say Tβ4. When it studies Ac-LKKTETQ, say TB-500 and give the sequence. Collapsing the two has already produced a literature that is hard to read.
— Stephan
Sourcing TB-500 for laboratory work
If your protocol calls for the fragment, our TB500 10mg research peptide ships lyophilized with a lot-specific Certificate of Analysis. Our Healing & Recovery category lists the related research materials. Our TB-500 research overview and buying guide cover specifications in more depth, and shipping and returns details the cold-chain handling from U.S. facilities. All products are for research use only.
Related materials researchers confuse with TB-500
Two other comparisons come up often. TB-500 is regularly set beside BPC-157, a different peptide with a different sequence and its own evidence base. We address that pairing in TB-500 vs BPC-157 purity verification. The other is thymosin alpha-1, which shares the thymosin name but is a separate peptide from a different family. Our thymosin alpha-1 5mg listing gives its own specification. Shared nomenclature is never evidence of shared structure or function.
FAQ
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is the full-length protein of about 43 amino acids. TB-500 is defined in U.S. federal records as an N-acetylated seven-residue fragment, Ac-LKKTETQ, corresponding to residues 17–23. Treat them as different substances unless a document defines TB-500 otherwise.
What is another name for TB-500?
The NIH/FDA registry gives the common name “N-terminal acetylated 17–23 fragment of thymosin beta 4.” That name is accurate when the material is the seven-residue peptide. It is not accurate for the full-length protein, and “thymosin beta-4” alone should not be used as a synonym.
What is the TB-500 sequence?
The registered sequence is LKKTETQ with an acetyl group on the N-terminus. A 2012 analytical study identified this fragment in a TB-500 formulation. Always confirm it against the mass spectrometry data for your specific lot.
Does TB-500 have the same research evidence as thymosin beta-4?
No. A 2026 review found that most studies evaluated thymosin beta-4, with direct TB-500 evidence limited to one included study. Findings on the full protein should not be assumed to apply to the fragment.
Sources
- FDA briefing document on TB-500, July 2026
- NIH/FDA GSRS record for TB-500
- Utilizing Developmentally Essential Secreted Peptides (PMC, 2021)
- Progress on the Function and Application of Thymosin β4 (PMC, 2021)
- Esposito et al., 2012, Drug Testing and Analysis
- PubMed record, N-terminal acetylated fragment study, 2012
- Simultaneous quantification of TB-500 and its metabolites, 2024
- Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, 2026
- Racing Medication and Testing Consortium TB-500 bulletin
- Safety and Efficacy of Approved and Unapproved Peptide Therapies, 2026
Recommended
This article summarizes published research for informational purposes. Products sold by Neo Lab Peptides are for laboratory research use only and are not intended for human or animal use.